Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 80.90% | 39.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 80.90% | 39.15% | |||
| Cost of Revenue | 672.56% | -34.40% | |||
| Gross Profit | 29.74% | 54.03% | |||
| SG&A Expenses | 48.66% | 17.21% | |||
| Depreciation & Amortization | 0.00% | 2.35% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 67.38% | 11.78% | |||
| Operating Income | -54.79% | 5.51% | |||
| Income Before Tax | -46.41% | 15.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -46.41% | 15.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -46.41% | 15.64% | |||
| EBIT | -54.79% | 5.51% | |||
| EBITDA | -57.34% | 5.84% | |||
| EPS Basic | -43.48% | 14.81% | |||
| Normalized Basic EPS | -40.00% | -7.14% | |||
| EPS Diluted | -43.48% | 14.81% | |||
| Normalized Diluted EPS | -40.00% | -7.14% | |||
| Average Basic Shares Outstanding | 0.14% | 0.81% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||